SCHEMBL673366

SCHEMBL673366

O=S(=O)(N(Cc1ccccc1)Cc1ccccc1)N(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.68
TSHR P16473 2/20 0.52
TAS2R14 Q9NYV8 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
ALDH1A1 P00352 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
KCNA5 P22460 1/20 0.50
POLB P06746 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CNR2 P34972 5/20 0.47
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
SLC6A4 P31645 1/20 0.45
MAPT P10636 1/20 0.45
FAAH O00519 1/20 0.44
PRSS1 P07477 1/20 0.44
PRSS2 P07478 1/20 0.44
ELANE P08246 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15673019 0.81 CA2 (0.63) CA2TSHRTAS2R14MEN1KMT2A
SCHEMBL1792267 0.81 CA2 (1.00) CA2TSHRTAS2R14MEN1KMT2A
SCHEMBL10312253 0.81 ALDH1A1 (0.64) CA2TSHRALDH1A1L3MBTL1POLB
SCHEMBL11594823 0.81 CA2 (0.63) CA2TSHRTAS2R14MEN1KMT2A
SCHEMBL984791 0.79 TAS2R14 (0.71) CA2TAS2R14MEN1KMT2AALDH1A1
Ethane SCHEMBL23927829 0.78 CA2 (0.59) CA2TSHRTAS2R14MEN1KMT2A
SCHEMBL11592312 0.78 CA2 (0.59) CA2TSHRTAS2R14MEN1KMT2A
SCHEMBL10788737 0.76 CNR2 (0.53) CA2TSHRMEN1KMT2AALDH1A1
SCHEMBL20490024 0.76 CA2 (0.57) CA2TSHRTAS2R14MEN1KMT2A
SCHEMBL20489988 0.76 CA2 (0.57) CA2TSHRTAS2R14MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10870724-B2 High heat monomers and methods of use thereof SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2020-12-22 US disclosed
US-10465037-B2 High heat monomers and methods of use thereof SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2019-11-05 US disclosed
US-20170158806-A1 HIGH HEAT MONOMERS AND METHODS OF USE THEREOF SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2017-06-08 US disclosed
EP-3172201-A1 HIGH HEAT MONOMERS AND METHODS OF USE THEREOF SABIC Global Technologies B.V. (NL) 2017-05-31 EP disclosed
WO-2016014536-A1 HIGH HEAT MONOMERS AND METHODS OF USE THEREOF SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2016-01-28 WO disclosed
US-9080046-B2 Epoxybenzyl-terminated poly(arylene ether)s, method for preparation thereof, and curable compositions comprising same SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2015-07-14 US disclosed
US-20140179828-A1 EPOXY RESIN COMPOSITIONS, METHODS OF MAKING SAME, AND ARTICLES THEREOF DOW GLOBAL TECHNOLOGIES LLC (US) 2014-06-26 US disclosed
EP-2746312-A2 Epoxy resin compositions, methods of making same, and articles thereof Dow Global Technologies LLC (US) 2014-06-25 EP disclosed
US-20140058014-A1 EPOXYBENZYL-TERMINATED POLY(ARYLENE ETHER)S, METHOD FOR PREPARATION THEREOF, AND CURABLE COMPOSITIONS COMPRISING SAME SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2014-02-27 US disclosed
US-8598281-B2 Epoxybenzyl-terminated poly(arylene ether)s, method for preparation thereof, and curable compositions comprising same SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2013-12-03 US disclosed
WO-2013032739-A2 EPOXYBENZYL-TERMINATED POLY(ARYLENE ETHER)S, METHOD FOR PREPARATION THEREOF, AND CURABLE COMPOSITIONS COMPRISING SAME SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2013-03-07 WO disclosed
US-8053077-B2 Composite-forming method, composites formed thereby, and printed circuit boards incorporating them SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2011-11-08 US disclosed
US-20100084170-A1 COMPOSITE-FORMING METHOD, COMPOSITES FORMED THEREBY, AND PRINTED CIRCUIT BOARDS INCORPORATING THEM SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2010-04-08 US disclosed
US-7655278-B2 Composite-forming method, composites formed thereby, and printed circuit boards incorporating them SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2010-02-02 US disclosed
US-20080178983-A1 COMPOSITE-FORMING METHOD, COMPOSITES FORMED THEREBY, AND PRINTED CIRCUIT BOARDS INCORPORATING THEM SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2008-07-31 US disclosed
EP-1351757-A2 COPOLYIMIDE GAS SEPARATION MEMBRANES L'air Liquide Société Anonyme pour l'étude et l'exploitation des procédés Georges Claude (FR) 2003-10-15 EP disclosed
WO-2002049747-A2 COPOLYIMIDE GAS SEPARATION MEMBRANES L'AIR LIQUIDE SOCIETE ANONYME A DIRECTOIRE ET CONSEIL DE SURVEILLANCE POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) 2002-06-27 WO disclosed
US-6383258-B1 FROM O-TOLIDINE SULFONE AND DIAMINE L'AIR LIQUIDE SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) 2002-05-07 US disclosed
US-5773533-A Epoxy resin reacted with carboxy-functional phosphinic or phosphonic acid and hardener HOECHST AKTIENGESELLSCHAFT (DE) 1998-06-30 US disclosed
US-4718921-A Method for removing water vapor from water vapor-containing gas UBE INDUSTRIES, LTD. (JP) 1988-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10870724-B2 High heat monomers and methods of use thereof HSP90AA1, HSP90AB1, EPHX2 CA2 3668/4885TSHR 4879/4885TAS2R14 4473/4885
US-20170158806-A1 HIGH HEAT MONOMERS AND METHODS OF USE THEREOF HSP90AA1, HSP90AB1, EPHX2 CA2 3668/4885TSHR 4879/4885TAS2R14 4473/4885
US-10465037-B2 High heat monomers and methods of use thereof HSP90AA1, HSP90AB2P, HSP90AB1 CA2 3686/4885TSHR 4878/4885TAS2R14 4423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.